# Monolabs Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/monolabs-co

- Industry: Food
- Headquarters: Seoul, South Korea
- Website: www.monolabs.io
- Total disclosed funding: $9.6M
- Latest round: Series B (Jul 1, 2022)
- Investors on record: 3

## About

Monolabs Co., Ltd., based in South Korea, specializes in digital healthcare solutions, focusing on personalized health supplements tailored to individual dietary needs through advanced algorithms.Founded in 2018 and headquartered in Seoul, South Korea, Monolabs Co., Ltd. operates in the digital healthcare sector, providing customized health supplements. The company has completed 4 deals, with its most recent funding round, a Series B, raising KRW 12.5 billion on July 1, 2022. This funding was led by CHUNGHO, with participation from other investors such as CTK Investment and Mainstreet Investment. CEO and founder Taehwan So has prior experience in entrepreneurship, although specific details about previous ventures are not available. The company has not undergone any significant pivots or changes in operations since its inception.Monolabs specializes in digital healthcare solutions, emphasizing personalized health supplements tailored to individual dietary needs through sophisticated algorithms. Their core offering includes a subscription-based service that provides customized nutritional supplements, formulated from over 100 million possible combinations to optimize health and wellness. The service allows users to receive tailored health products directly at home, enhancing their personal wellness journey. Monolabs targets health-conscious consumers primarily in South Korea but aims to expand into other international markets, addressing the growing demand for personalized health solutions in various geographic regions.Monolabs generates revenue primarily through its subscription model, where customers pay for ongoing delivery of customized health supplements. The company engages directly with consumers, facilitating a seamless purchasing experience that fosters customer loyalty. While specific pricing details are not disclosed, the revenue structure is based on recurring monthly fees or quarterly subscriptions, providing a steady income stream. The flagship products include uniquely formulated health supplements that leverage the company's advanced algorithms to meet specific nutritional needs, positioning Monolabs in the personalized health space.In July 2022, Monolabs raised KRW 12.5 billion in Series B funding, which will be used to diversify its business into areas such as drug distribution and telemedicine. The company aims to develop new products and expand its market presence beyond South Korea into other international regions. Specific details regarding the release dates for upcoming products or targeted markets for expansion have not been disclosed.

## Funding rounds

- Series B, Jul 1, 2022, $9.6M — CTK Investment, Mainstreet Investment, CHUNGHO

## Investors

- CTK Investment (https://capitalatlas.ai/funds/ctk-investment) — Series B
- Mainstreet Investment (https://capitalatlas.ai/funds/mainstreet-investment) — Series B
- CHUNGHO — Series B